Phase 4 Study of effect of Aspirin on Flushing in DMF-Treated Subjects

• Research type

  Research Study

• Full title

  A Phase 4, Randomized, Double-Blind Study with a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects with Relapsing-Remitting Multiple Sclerosis Treated with Tecfidera™ (dimethyl fumarate) delayed-release capsules

• IRAS ID

  134025

• Contact name

  David Rog

• Contact email

  david.rog@srft.nhs.uk

• Sponsor organisation

  Biogen Idec Research Ltd.

• Eudract number

  2013-001895-40

• ISRCTN Number

  n/a

• REC name

  East of England - Cambridge South Research Ethics Committee

• REC reference

  14/EE/0076

• Date of REC Opinion

  5 Jun 2014

• REC opinion

  Further Information Favourable Opinion